Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy

Abstract

Key Points The posttreatment end point progression of FL within 24 months (POD24) is strongly associated with OS. A pretreatment clinicogenetic risk model (m7-FLIPI) predicts POD24 and OS and identifies the smallest subgroup with highest unmet need.